Send us Fan Mail

Steve Anderson explains why Renue Medical Centre, his specialty hospital in Nuevo Vallarta, puts physical therapy and orthobiologics ahead of surgery. He contrasts that pathway with the surgery-first habit in the United States and Canada, then covers induced pluripotent stem cells, diabetes trials, and the cost of treating cell deficits late. Listeners also hear who pays for longevity care, and why organ replacement is moving faster than most patients think.

Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Drug approval rewards a single patented product proven in large trials.

Dr. Francisco Contreras of Oasis of Hope argues that this model leaves out personalized cell therapies and cheap natural compounds that no company will pay to test.

We discuss why the FDA standard exists and asks whether government-funded studies should fill the gap to fund the evidence for products without a patent. A frank conversation about cancer, drugs, and alternative therapies.

LinkedIn

Company Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Health systems pay to bring patients to their website, then lose them at the search box.

Chris Pace of SearchStax, who was the former Sr. Director of Marketing for Banner Health. He was a SearchStax customer who was so confident in the product, he joined SearchStax.

Chris explains why owned search is the most ignored part of digital access. He shares how a chest pain search once returned a blog post, how a moved MyChart login drove up calls to one call center, and what search data reveals about unmet demand.

LinkedIn

Company Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Most families with an undiagnosed genetic disease spend about seven years getting an answer. Josh Resnikoff, founder and CEO of Sunstone Health, compresses that to twelve weeks. He explains how his software reads health insurance claims the way a clinician reads a chart, surfaces children before anyone has diagnosed them, and hands a complete packet back to the family's own pediatrician. He also tells you why his second son is the reason.

LinkedIn

Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Dr. Munir Ghesani is the Chief Medical Officer of United Theranostics. This company brings together leaders in nuclear medicine, radiology, molecular imaging, radiopharmaceutical therapy, clinical trials, and medical informatics to expand access to advanced cancer care in community practice.

Dr. Munir Ghesani reduces an entire field to two sentences: we see what we treat, and we treat what we see. He explains how a molecule homes to a prostate cancer cell, carries a radioisotope inside it, and then reports its own position back to a scanner. Chemotherapy cannot do that. He also traces the idea to 1940 and names the two things that finally made it work.

LinkedIn

United Theranostics

See More ChalkTalkJim Episodes

Send us Fan Mail

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, explains why the world still has no true prophylactic cancer vaccine, and why his team believes breast cancer is where that changes.

He walks through the protein that makes the approach possible, the phase one safety and immune-response data from 35 women, the higher bar a vaccine for healthy people must clear, and the capital problem facing biotech as investors chase AI.

LinkedIn

Company Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Neill Marshall and Kurt Mosley of HealthSearch Partners have placed hospital and health system leaders for more than three decades. They explain why the first 90 days in a new executive role predict whether a CEO is still in the chair in year five, why boards push for change too fast, and why trust must be built before anything changes. Practical tactics drawn from 30 interviews with sitting health system leaders.

Website

LinkedIn:

Kurt Mosley

Neill Marshall

See More ChalkTalkJim Episodes

Send us Fan Mail

Most people get insurance through an employer or an exchange and never think about how carriers actually reach them. Mike Smith has spent 33 years in the channel, recruiting independent agents in all 50 states and getting paid only when someone enrolls. He explains how the wholesale model works, why it costs the consumer nothing, and what a person can do that a comparison website cannot.

LinkedIn

See More ChalkTalkJim Episodes